Phase 1b study showed dose-dependent and sustained reduction of tau protein in cerebrospinal fluid through open-label long-term extension (LTE) IONIS-MAPT Rx reduced aggregated tau pathology across all brain composites assessed starting as early as week 25 through week 100 CARLSBAD, Calif.
What is the CRM Ionis Young Investigator Grant (YIG)? Ionis Pharmaceuticals is pleased to announce the Ionis CRM Young Investigator Grant (YIG). This grant was recently created by the division of CardioRenal-Metabolism within Medical Affairs to recognize early career investigators who are performing high quality research in the field of severe hypertriglyceridemia. Ionis values developing […]
Ionis recognizes the importance of Independent Medical Education (IME) and is committed to supporting programs that seek to advance clinical care. Ionis supports targeted high-quality accredited and non-accredited medical education programs to advance excellence in healthcare by improving disease awareness, clinical knowledge, and multidisciplinary management within our therapeutic areas of focus. IME is defined as […]
Ionis Pharmaceuticals, which recently announced it will open a sprawling research-and-development center in Oceanside, also plans a large expansion of its home base in Carlsbad.
About 20% of the global population and one in five U.S. adults have elevated levels of lipoprotein(a), a complex form of LDL that strongly predicts risk for coronary disease and aortic valve stenosis. Evidence for a causal association between Lp(a) concentration, which is primarily genetically determined, and CV outcomes across ethnicities continues to build.